SynthesisBMC ophthalmology2026
The effectiveness of atropine 0.05% eye drops versus placebo on controlling myopia progression among school children in randomized controlled trials: a systematic review and meta analysis.
Synthesis in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Choroidal Structural and Vascular Changes During Myopia Progression and in Response to Myopia Control Interventions: A Systematic Review.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParticularly in children, atropine eye drops have demonstrated encouraging results in reducing the progression of myopia. Nevertheless, there is insufficient data regarding the single dose atropine 0.05% eye drop’s ability to stop the progression of myopia, despite several studies published in various treatment types and combined comparisons of myopia progression controls. Randomized clinical trial studies measuring spherical equivalent and axial length change outcomes in school-age myopic children without any other health issues that used atropine 0.05% therapy with a placebo control group were eligible for this review.
objectiveto synthesize evidence on the effectiveness and safety of atropine 0.05% versus spectacle eye glass to control myopia progression among children with 6 to 12 years of age, 2025.
methodsThis review followed the PRISMA 2020 guidelines, and JBI SUMARI software was used to carry out the step-by-step procedures from the research topic to data extraction and analysis, including the methodological quality assessment using the JBI critical appraisal check list. The Cochrane GRADEpro evaluation was used to evaluate the degree of certainty in the evidence. The mean difference, inverse I square, and 95% confidence interval were used to express the effect magnitude. The publishing bias was analysed using a funnel plot using STATA 16 software.
resultsA total of 1967 children from eleven studies were included in this study. When compared to a placebo group, atropine 0.05% eye drop has demonstrated a statistically significant decrease in the progression of myopia; the pooled mean SE and AL reduction of myopia progression was − 0.49 dioptres per year (-0.32, -0.57) and 0.18 millimetres per year (0.12, 0.23), respectively. The mean SE reduction with atropine 0.05% eye drop was − 0.41Ds/yr (-0.30, -0.52) in Asian studies and − 0.65Ds/yr (-0.14, -1.16) in non-Asian studies, according to subgroup analysis.
conclusionAtropine 0.05% eye drops had a significant effect on slowing the progression of myopia over spectacle, given the lack of generalizability and greater heterogeneity across the trials examined in this review. This review has been registered in PROSPERO since 04 November 2024 with registration ID: CRD42024604462.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.